Parkinson’s Disease - Efficacy, Safety and Tolerability of CoganeTM (B10-046)
Protocol ID
B10-046
Protocol Description
The purpose of the study is to find out if CoganeTM works (that is, can it improve the symptoms of PD or prevent them from worsening), is safe and well tolerated in patients with early-stage PD and to determine how the body deals with CoganeTM.
The study drug is supplied as a liquid which you should take once a day with a meal e.g. breakfast or lunch.
Eligibility Criteria
• Men and women between the ages 35 - 75
• Persons diagnosed with idiopathic Parkinson’s disease for less than 5 years
• Persons not taking any Parkinson’s medication
Primary Investigator(s)
- Andrew Feigin, MD